. The cytosol assay presents some problems however, the most important of which is the need to take great care to ensure that tumour tissue is transported and stored at low temperature to prevent loss of binding activity. Other problems include the amount of tissue required, the length of time taken to complete the assay and the limited number of samples that can be measured at any one time. Histological confirmation of the quality of tissue used for assay is not always possible and in some samples the tumour tissue is inevitably diluted by surrounding stroma and occasionally necrotic material giving erroneously low or negative results. Conversely, low positive results can occasionally be obtained from ER-negative tumours with strongly positive cells in surrounding normal breast ducts.
It was realised that these problems could be overcome by the use of specific antibodies against the ER protein. It took some time, however, before the first of such antibodies were developed by Greene and colleagues in 1980 and their use in a cytosol enzyme immunoassay (EIA) described by King et al. (1985) . The availability of anti-ER antibodies also created the opportunity for the development of immunohistochemical assays on tissue sections. The first commercial ER immunohistochemical assay (ERICA) was available in kit form from Abbott Laboratories using antibody H222 on frozen tissue sections. The use of enzyme antigen retrieval techniques was of limited success in applying this antibody to routinely fixed tissue.
However, the recent introduction of antibodies such as ER ID5 (Al Saati et al., 1993) which can be used on fixed, paraffin-embedded sections after heat-mediated antigen retrieval, has recently changed the situation dramatically. Instead of being carried out in biochemistry or clinical chemistry laboratories, assays can now be done as part of the routine histopathological assessment of breast tumour tissues. In parallel with the development of antibodies to ER has been the production of antibodies to progesterone receptors (PRs). Unlike ER, the original PR antibody KD68 (Press and Greene, 1988) , available from Abbott Laboratories, worked satisfactorily on formalin-fixed paraffin-embedded tissue as well as on frozen tissue (Bobrow et al., 1994) . Other antibodies to PR e.g. NCL PGR have now been produced which also give good results on fixed material (Taylor et al., 1994) after antigen retrieval and are generally less expensive.
As with the introduction of all new techniques, the results obtained with these latest immunohistochemical assays had to be validated against results from established LBA techniques. There are several published studies in which this has been done and they show generally good agreement between the overall findings with the two methods (Andersen et al., 1990; Saccani Jotti et al., 1994) . Early studies using the immunohistochemical assay on fixed tissue sections suggest that the results are clinically relevant (Goulding et al., 1995; Veronese et al., 1995) . However, there is no general agreement as to how the immunohistochemical assay should be evaluated and several different methods for scoring sections have been described (Kinsel et al., 1989; Remmele and Stegner, 1987; Reiner et al., 1990) . Now that antibodies like ER ID5 have opened up the possibility of many retrospective and prospective studies there is a pressing need for quality assurance of both the technical reproducibility of staining and the method of assessment. The first is relatively easy, provided that adequate positive and negative controls are used, but the second is much more difficult to achieve. It is extremely important that agreement on a scoring method should be reached so that comparisons can be made between results obtained from different laboratories.
We have used ER ID5 to stain formalin-fixed paraffinembedded tissue sections of mammary carcinoma tissue from 170 women treated with tamoxifen for metastatic disease. Evaluation of ER using immunohistochemistry has been compared with results obtained from the LBA on tumour tissue cytosol. We have further used several different ways of evaluating stained tissue sections in an attempt to ascertain which is the most clinically relevant. We have also looked at the additional value of assessing PR status by immunohistochemistry to find out whether this improves the clinical predictive ability of ER.
Materials and methods Patients
The study group consisted of 170 women who received firstline tamoxifen treatment for evaluable metastatic breast cancer. A total of 133 patients had presented with operable primary disease (41 had node-negative disease, 86 nodepositive disease and in six the node status was not known), 23 had locally advanced disease and 14 had distant metastases at presentation. None of the patients had received prior adjuvant systemic therapy.
The patients have been followed-up for a median of 16.6 years (range 1 -17.6 years). Diagnosis and date of recurrence was determined in a standard manner according to the criteria of Hayward et al. (1978) and response to treatment was assessed by UICC criteria (Hayward et al., 1977) . Response was classified as either complete/partial (responders) or static/progressive disease (non-responders). Results obtained on a subset of these patients have been described previously (Barnes and Millis, 1995) . Patients' details are given in Table I .
Histological assessment Tumours were typed according to WHO criteria. Histological grade was determined by one of the authors (RRM) according to the method of Bloom and Richardson with modifications as suggested by Elston (1984) . (Table I ). (n = 14) . Tissue adjacent to that taken for the cytosol assay was always assessed histologically to ensure that it was representative of the tumour as a whole. Retrospective immunohistochemical assay was performed on routine formalin-fixed paraffin-embedded tissue sections which had been taken from the above. As an attempt was always made to cut sections from a block which contained some normal ducts, inevitably the two assays were frequently carried out on different pieces of tissue. The receptor status in infiltrating carcinomas is generally consistent throughout the tumour and within metastases therefore the fact that different blocks were used in some cases should not be of relevance. PR was only determined retrospectively by immunohistochemistry.
Immunohistochemical assay Sections of tumour were placed onto APES or vectabondcoated slides and dried for 60 min at 56°C. After blocking endogenous peroxidase activity, sections were placed in a plastic rack in a microwaveable dish containing 0.01 M citrate buffer, pH 6.0. Sections were microwaved for 3 x 10 min on 70% power in a 800 watt microwave oven and then removed and allowed to cool to room temperature. After rinsing in distilled water, followed by 0.01 M phosphate-buffered saline pH 7.6 (PBS), sections were covered with 20% normal rabbit serum in PBS to block non-specific binding. ER ID5 monoclonal antibody (Dako) diluted 1:100 in PBS was applied for 1 h at room temperature. After thorough rinsing in PBS ( x 3) sections were covered with FAB 2 biotinylated rabbit anti-mouse Ig antibody (Dako) Response to tamoxifen, complete or partial was seen in 87/170 (51%) of cases. This high proportion of women showing a positive response is almost certainly due to the prior selection of patients in the study which was based on their known response to hormone treatment. Since the purpose of the study was to relate ER status to response women with unevaluable disease were excluded. The actual percentage of patients with ER-positive tumours depends upon both the method of assay and the method of assessment of staining. The cytosol assay with a cut-off of 20 fmol mg-' found 126/170 (74%) of tumours to be positive. The immunohistochemical assay using the histo score with a cut-off of 100 found 112/170 (65%) of cases to be positive. With all of the other methods of evaluation, 32/170 (19%) of cases were totally negative and 81 % showed some level of staining, but the overall number of tumours designated as positive or negative depended on the method of evaluation used. As seen in Table II the proportion of positive cases ranged from 31% (IRS) to 69% (simplified category score) (strong + moderate). Using the simplified category score, 58 cases (34%) were PR-positive. This is a lower proportion than is usually found in an unselected group of patients where approximately 50% of the cases are PRpositive. Examples of positive staining patterns are shown in Figure 1 .
The Kaplan-Meier plots in Figure 2 show that all the methods of assay and evaluation of ER gave significant results when used to predict the duration of response. The cytosol assay gave the lowest level of significance (X2 11.91, P<0.001 the other 13 cases cytosol values were negative, three were also ER-negative by immunohistochemistry (but two were PR-positive), the others all showed immunostaining with two being weak, five moderate and three strong stainers. There were 41 cases with positive ER results both by cytosol assay and by immunohistochemistry (22 with strong staining and 19 with moderate staining), who failed to respond to tamoxifen. All of these patients had one or more of the following poor prognostic features: PR negativity, large tumour size or heavy nodal involvement, the latter two showing that when the tumour burden is overwhelming ER status has little influence on disease outcome.
Discussion
These results are in agreement with the findings of Goulding et al. (1995) and confirm that highly significant clinical information can be obtained from the determination of ER using an immunohistochemical evaluation. Whatever scoring method is used, in this study we show that immunohistochemistry gives superior results to the cytosol assay as it is more closely related to patient outcome. The ligand binding assay was done up to 17 years ago and there has been a general improvement in cytosol assays since the early days. Although it is perhaps unfair to compare methodology of 17 years ago with a current immunohistochemical technique it is also true to say that one of the consequences of the general improvement in cytosol assays has been an increase in the number of cases found to be positive which has resulted in some reduction in the sensitivity of the technique. In the present study we have shown that immunohistochemistry can give results which are clinically relevant, a very important factor now that small tumours are being diagnosed with increasing frequency and no tissue is available for the cytosol assay. Another advantage of the histological method on paraffin-embedded tissue is that the cellularity of the tumour can be taken into consideration when evaluating the staining (Underwood, 1983) .
All the methods of scoring used in this study with ER ID5 gave significant results, therefore the method of choice will depend upon further studies into which is the most acceptable and gives the most consistent intra-and inter-observer reproducibility. It is important to select a method which is easy and quick to apply and is reproducible. When it became obvious that not all ER-positive tumours respond to hormone treatment other indicators of response were sought. Horwitz and McGuire (1975) suggested that PR, an oestrogen-induced protein, should also be measured. The theory was that the coexpression of PR would indicate that the ER in the tumour was functionally active. In practice, the measurement of the two receptors does improve predictive accuracy: ER-positive PR-positive tumours have approximately 80% likelihood of responding whereas doublenegative tumours have a less than 10% likelihood of response (Stewart et al., 1982) . However, half of the ERpositive PR-negative tumours also show a favourable response. Therefore if, as has been suggested, only PR status was evaluated a significant number of patients who would respond might be denied endocrine treatment. Our results in this study are consistent with these findings. More recently other oestrogen-induced proteins such as cathepsin D and PS2 have been studied but neither of these alone or in combination with ER have proved to be outstandingly successful in refining response prediction.
The use of immunohistochemistry for the measurement of ER has many advantages, some of which have been outlined above. Not least is the great reduction in cost of the assays which have followed the introduction of the newer antibodies. In the current times of financial stringency, this factor is of increasing relevance. The assay is now easier to do and the results should become more reliable with improvements in quality control. It is likely that ER will have a continuing role in the management of patients with breast cancer and interlaboratory consistencies will improve as agreement is reached as to the best method of scoring. Nevertheless, the assays should only be carried out when the results are going to be of either practical clinical or research value.
